�Urodynamix Technologies Ltd. (TSX-V:URO) announced that it has received a non-refundable financial contribution from the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) to help accelerate the development and commercialization of new NIRS technology for the detection of prostate gland cancer during the digital rectal examination, or DRE.
Urodynamix's unexampled technology, based on approximate infrared spectrographic analysis (NIRS), is designed to aid in the diagnosis and discussion of prostate cancer and related diseases in a physician office setting. During the DRE screening prove for prostate cancer, a physician inserts a gloved finger into the rectum in order to be able to feel the size, shape, and texture of the prostate and other nearby organs. The sensitivity and specificity of DRE ar highly subjective and dependent upon the skill of the mD, his or her ability to interpret what he or she feels, and the nature and progression of the disease. NIRS technology will allow physicians to notice and study abnormal prostate tissue and provide documentary, clinically meaningful data to help doctors make better diagnostic decisions.
NRC-IRAP provides technology and business advisory services, conjugated with shared financial support to innovative companies and organizations. NRC-IRAP will contribute approximately $60,000 over the next 8 months to reenforcement the development of NIRS technology victimized to notice, diagnose and monitor prostate cancer and related conditions.
"This financial support from the Government of Canada through the NRC-IRAP course of study will give up us to develop our next generation products more quickly and address a large grocery store opportunity for improved prostate gland cancer diagnosis and monitoring using our NIRS engineering platform," aforesaid Barry Allen, President and CEO.
In North America, Europe and Japan, an estimated 40 million men have prostate gland cancer and 150 one thousand thousand men qualify for annual prostate cancer screening. Prostate cancer treatment and unneeded biopsies price $10 1000000000000 per year in the US lonely. Urodynamix's NIRS technology may help growth cancer catching rates by providing an objective measure of blood flow in the prostate gland gland. The device is also expected to be used in conjunction with transrectal echography imaging to help ameliorate the accuracy of targeted prostate biopsy and treatment.
About Urodynamix Technologies Ltd.
Urodynamix Technologies is a Canadian aesculapian device troupe developing and commercializing noninvasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is presently focused on products that aid in the diagnosing and treatment of urinary incontinence, let down urinary parcel of land symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal atmospheric pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough medical technology has the potentiality to beneficially affect more than 200 million people worldwide.
Certain information contained in this press handout may be forward-looking and is case to unknown risks, which could drive actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are fair, it crapper give no assurance that such expectations will rise correct. The TSX Venture Exchange has not reviewed and does not assume responsibility for the adequateness or accuracy of this release.
http://www.urodynamix.com
More info
Monday, 1 September 2008
Subscribe to:
Posts (Atom)